• Harry Sokol, Tatiana Galperine, Nathalie Kapel, Pierre Bourlioux, Philippe Seksik, Frederic Barbut, Julien Scanzi, François Chast, Rui Batista, Francisca Joly, Anne-Christine Joly, Anne Collignon, Benoit Guery, Laurent Beaugerie, and French Group of Faecal microbiota Transplantation (FGFT).
• Gastroenterology and Nutrition Department, AP-HP, Saint-Antoine Hospital and UPMC Paris 06 University, GRC n°03, SUVIMIC, Paris, France. Electronic address: harry.sokol@aphp.fr.
• Dig Liver Dis. 2016 Mar 1; 48 (3): 242-7.

AbstractFaecal microbiota transplantation is effective for treating recurrent forms of Clostridium difficile infection and its use in this indication is recommended in the most recent European and North American guidelines. In this context, faecal microbiota transplantation is beginning to be performed in France in clinical practice, while the rules governing this procedure have been defined in France only for clinical trials. To unify, secure, and evaluate practice in this field in France, the French Group of Faecal microbiota Transplantation (FGFT) was created in October 2014 with the support of the French National Society of Gastroenterology, the French Infectious Disease Society, and the National Academy of Pharmacy. We present here the deliberations of this group regarding the use of faecal microbiota transplantation for recurrent Clostridium difficile infection. The issues addressed are the indications, therapeutic sequence, delivery procedures, donor selection, methods and conditions of specimen preparation, and traceability. Copyright © 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

16 keywords...

hide…